Portola Pharmaceuticals, Inc. Discovering and developing novel therapeutics.

Description: Portola Pharmaceuticals is a biopharmaceutical company developing innovative drugs for the treatment of cardiovascular and inflammatory diseases Portolas two most advanced programs are in Phase II clinical trials: 1) betrixaban, an oral, once-daily Factor Xa inhibitor being developed for stroke prevention in patients with atrial fibrillation (SPAF) and for prevention of venous thromboembolism (VTE) in various patient populations, and 2) elinogrel, a direct-acting, reversible oral and i.v. ADP receptor antagonist initially being developed for patients with acute coronary syndrome (ACS).

Keywords: biopharmaceutical company, innovative drugs, treatment of cardiovascular diseases, inflammatory diseases, betrixaban, Factor Xa inhibitor, stroke prevention, atrial fibrillation, prevention of venous thromboembolism, elinogrel, oral and i.v. ADP receptor antagonist, acute coronary syndrome, antithrombotic, thrombosis, inflammatory diseases

Tags: portolapharm, portola, pharmaceuticals, profiles, developing, therapeutics, novel, discovering, inhibitor, overview, thrombosis, company, prt, syk, programs, jak, oral, diseases, news, board, prevention, elinogrel, betrixaban, inflammatory, publications, areas, therapeutic, pipeline, newsroom, product, pdf, trials, clinical, inflammation, dual, development, specific, directors, acute, stroke,

Portolapharm.net

Content Revalency: Title: 50.00%   Description: 60.00%   Keywords: 78.12%  |  Document size: 9,196 bytes
More info: Whois - Trace Route - RBL Check